Intuitive Surgical (NDQ:ISRG): This robotic surgery pioneer has faced plenty of headwinds in 2026!

Intuitive Surgical (NDQ:ISRG) is one of the most important companies in modern medical technology. It pioneered robotic‑assisted surgery, built a global installed base that competitors have spent decades trying to replicate, and created one of the most durable recurring‑revenue machines in healthcare. But this does not mean it has been immune from challenges and has had its fair share in 2026. Is this a buying opportunity?

Intuitive Surgical’s history and overview

Intuitive Suegical was founded in 1995 and received FDA clearance for the first da Vinci system in 2000. That moment changed the trajectory of minimally invasive surgery. Over the next two decades, Intuitive expanded from a niche technology provider into a global platform company with more than 11,000 systems installed worldwide and a procedure ecosystem that continues to compound.

The company’s commercial model has always been the real engine. Selling a da Vinci system is only the beginning. The recurring revenue from instruments, accessories and services now accounts for roughly 75–86% of total revenue, depending on the quarter. That annuity‑like structure is what allowed Intuitive to grow revenue at an annualised rate of 18–20% over the last five years, even as the broader medtech sector cycled through reimbursement pressure, hospital budget constraints and supply‑chain volatility. By 2026, Intuitive had become a Fortune 500 company, ranking 459th overall and 43rd in healthcare, with a market capitalisation of roughly US$146bn and a forward P/E of around 38–40x.

The stock itself has been volatile. After peaking above US$600 in early 2025, Intuitive entered 2026 trading near US$412, close to its 52‑week low of US$396.68. The share price is down roughly 25–30% year‑to‑date, reflecting a combination of sector‑wide valuation compression and company‑specific concerns. Let’s dive into the latter

Intuitive’s 2026 Challenges: Competition, Pricing Pressure and a Sentiment Reset

ntuitive’s fundamentals remained strong, but the narrative around the stock deteriorated sharply. In our view, the share‑price decline was driven by three intertwined forces: competitive anxiety, geographic pricing pressure and a broader derating in medtech valuations.

The first issue was competition, particularly from China. Domestic Chinese surgical‑robot manufacturers gained share in public tenders, and government‑driven pricing pressure weighed on Intuitive’s procedure growth in the region. Management acknowledged that China procedure volumes were running below the corporate average, held back by light tender activity and domestic rivals’ momentum. Investors began to question whether Intuitive’s long‑standing dominance could be eroded in one of the world’s most important growth markets.

The second issue was a new fear: the idea that OpenAI’s move into robotics could eventually extend into surgical robotics – eerily similar to fears software companies are seeing their investors express. This was speculative, and nonsense in our view, but it was enough to spook a market already on edge. The concern was not that OpenAI would release a surgical robot tomorrow, but that the competitive moat around Intuitive’s software, data and machine‑learning capabilities might not be as impregnable as previously assumed. The market tends to overreact to existential threats, and this was no exception.

The third issue was macro‑driven. Hospitals in Japan and the UK faced budget constraints, bariatric procedure volumes declined for six consecutive quarters, and tariffs and product‑mix shifts compressed gross margins by around 90 basis points year‑on‑year in Q3. These pressures were not catastrophic, but they fed into a narrative that Intuitive’s growth might be slowing at the margin.

Despite these headwinds, the underlying business continued to perform. Q1 2026 revenue grew 23% year‑on‑year to US$2.77bn, with adjusted EPS of US$2.50, beating consensus by nearly 19%. Procedure growth remained robust at 17%, and the installed base grew 12% to 11,395 systems. Recurring revenue reached 86% of total sales. The da Vinci 5 platform gained traction, with nearly 1,500 systems in use.

Are these the numbers of a company in structural decline? We’d argue no, but markets trade on expectations, not just results. The combination of competitive noise, valuation compression and macro uncertainty created a sentiment reset. Intuitive’s forward P/E fell from a five‑year average of ~70x to the high‑30s. Analysts trimmed price targets. Deutsche Bank cut its target to US$366. Others reduced targets while maintaining Buy ratings. The stock’s derating was as much about the sector as it was about the company.

Consensus estimates look optimistic

The final third of the story is about why analysts remain optimistic despite the drawdown. The consensus view is that Intuitive’s long‑term growth drivers remain intact: procedure expansion, installed‑base growth, recurring revenue leverage and the rollout of next‑generation platforms.
Consensus EPS for 2026 is US$10.42, rising to US$11.79 in 2027. With approximately 354.4m shares on issue, the implied net income is: US$3.69bn and US$4.18bn respectively.

These figures align with the broader narrative that Intuitive is still a high‑growth, high‑margin compounder. Analysts expect revenue to grow from US$11.7bn in 2026 to US$13.3bn in 2027, with EBITDA rising accordingly. The long‑term growth estimate sits around 15.5%.

Why the optimism? First, the procedure engine remains powerful. Worldwide da Vinci procedure growth continues to run in the mid‑teens, and management raised its full‑year 2026 outlook to 13.5–15.5%. Procedure growth is the single most important driver of recurring revenue, and recurring revenue is the core of the model.

Second, the installed base continues to expand. Intuitive placed 431 systems in Q1 2026, up from 367 a year earlier. Every new system expands the annuity stream. Third, the da Vinci 5 platform is still early in its adoption curve. Higher pricing, higher utilisation and higher instrument revenue per procedure all support margin expansion over time.

Fourth, analysts believe the competitive fears are overstated. Chinese competitors may gain share domestically, but Intuitive’s global footprint, regulatory approvals, clinical data and surgeon‑training ecosystem remain unmatched. As for OpenAI, analysts view the risk as distant and speculative.

And finally, valuation resets often create opportunity. The average 12‑month price target is around US$559–565, implying 30–35% upside from current levels. The bullish case is that Intuitive has been through similar drawdowns before and emerged stronger. And this is the mean share price range.

Conclusion

In our view, the investment case for Intuitive Suegical hinges on whether the 2026 headwinds represent a temporary air pocket or a structural shift. The evidence so far suggests the former. The fundamentals remain intact, the competitive moat remains wide, and the long‑term growth drivers remain powerful. The stock may no longer trade at 70x earnings, but a high‑30s multiple for a company with mid‑teens growth, dominant market share and expanding recurring revenue still looks justified.